Neogen Corporation

NASDAQ:NEOG

Medical - Diagnostics & Research

Healthcare
$11.08 +1.79%

+$0.16 today

Market cap
$2.42B
Beta
1.80
P/E (TTM)
-3.3
EPS (TTM)
-$2.80
52W Low $4.56High $11.43

Volume 1.79M

Average 2.53M

NEOG EBITDA Margin

EBITDA as a percentage of revenue.

Neogen CorporationNASDAQ: NEOG

EBITDA Margin · Q1 FY2027 · quarter ended Aug 2026

EBITDA Margin narrows to 12.6%

EBITDA Margin was 12.6% in Q1 FY2027, down 30.1 pp from a year earlier. On a trailing-twelve-month basis it was 11.9%, up 111.0 pp year over year. Over 3 fiscal years it widened by 3.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 29.0% for the fiscal year ending May 2027, up from 18.9% in FY2026.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterAug 2026
12.6%-1.3 pp QoQ
Last fiscal yearMay 2026
18.9%+123.8 pp YoY
LTMAug 2026
11.9%+111.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-30.1 pp+15.8 pp+45.9 pp
1 year+123.8 pp+10.0 pp-113.7 pp
3 years+3.8 pp+16.3 pp+12.5 pp
5 years+10.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2026
18.9%
Year-over-year change
+123.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NEOG compares with its peers on the latest reported figures

  • NEOG's LTM Aug 2026 EBITDA Margin of 11.9% is the lowest of the 7 companies compared; the peer median is 22.9%.
  • Its year-over-year change of +111.0 pp is the highest of 7, against a peer median of -0.5 pp.
  • Over three fiscal years its change of +3.8 pp compares with a peer median of +2.6 pp.
NEOG Competitors Peer median
EBITDA Margin for NEOG and competitors
Company Period LTM level YoY 3-year change
ZTSZoetis Inc.LTM Jun 202642.0% -1.1 pp+1.4 pp
IDXXIDEXX Laboratories, Inc.LTM Sep 202634.9% +0.0 pp+4.9 pp
BCPCBalchem CorporationLTM Sep 202624.8% +0.2 pp+3.8 pp
MRKMerck & Co., Inc.LTM Jun 202621.0% -18.3 pp+7.6 pp
PAHCPhibro Animal Health CorporationLTM Mar 202615.0% +4.5 pp-1.1 pp
ELANElanco Animal Health IncorporatedLTM Sep 202613.2% -6.2 pp-5.3 pp
NEOGNeogen CorporationLTM Aug 202611.9% +111.0 pp+3.8 pp
Peer median (excluding NEOG) 22.9%-0.5 pp+2.6 pp

Competitors are the stored peer set for NEOG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
FY2026
May 2026
Revenue527.16M822.45M924.22M894.66M870.4M
Cost of Revenue284.15M416.49M461.59M473.29M461.9M
Gross Profit243.01M405.96M462.64M421.38M408.5M
Gross Margin46.1%49.4%50.1%47.1%46.9%
Research & Development17.05M26.04M22.48M21.09M18.4M
Selling, General & Admin167.35M342.4M382.76M401.97M411.7M
Operating Expenses184.4M368.44M385.21M411.96M430.1M
Depreciation & Amortization24.13M90.47M121.23M125.67M116.3M
EBITDA84.34M124.39M182.6M(937.75M)164.9M
EBITDA Margin16.0%15.1%19.8%-104.8%18.9%
Operating Income58.62M37.52M77.43M9.42M(21.6M)
Operating Margin11.1%4.6%8.4%1.1%-2.5%
Interest Income1.34M3.17M6.36M3.11M0
Interest Expense72K55.96M73.39M71.62M57.6M
Other Income / Expenses1.59M(59.56M)(91.73M)(1.14B)12.6M
Income Before Tax60.21M(22.04M)(14.31M)(1.13B)(9M)
Pre-Tax Margin11.4%-2.7%-1.5%-126.7%-1.0%
Income Tax Expense11.9M828K(4.88M)(41.07M)(1.1M)
Net Income48.31M(22.87M)(9.42M)(1.09B)(7.9M)
Net Margin9.2%-2.8%-1.0%-122.1%-0.9%
EPS (Basic)0.45(0.12)(0.04)(5.03)(0.04)
EPS (Diluted)0.45(0.12)(0.04)(5.03)(0.04)
Weighted Avg Shares107.68M188.88M216.48M216.89M217.5M
Weighted Avg Shares (Diluted)108.02M188.88M216.48M216.89M217.5M

Neogen Corporation

NASDAQ:NEOG

Intrinsic Alpha fair value

Locked

Current Price

$11.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.